SOURCE: InNexus Biotechnolgy, Inc.

March 02, 2007 13:32 ET

InNexus Biotechnology Podcast Available on

VANCOUVER, BC -- (MARKET WIRE) -- March 2, 2007 -- If you missed MN1's interview with Jeff Morhet, President, CEO & Chairman of InNexus Biotechnology, Inc. (OTCBB: IXSBF) (TSX-V: IXS), Feb. 26, 2007, at 11:00 a.m. CDT, you can still catch it by downloading the podcast on

Mr. Morhet updated the investment community with the Company's latest ventures and the markets it serves, recent press releases, current capitalization, and its strategic and financial outlook for the remainder of Fiscal 2007.

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking technology (DXL™) improving the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.

Again, to access the podcast in its entirety, go to and download the podcast. For information on InNexus Biotechnology, Inc., go to


Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live radio web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

Contact Information

  • Contacts:

    Jeff Morhet
    President, CEO & Chairman
    InNexus Biotechnology, Inc.
    13208 E. Shea Blvd.
    Mayo Clinic Campus Collaborative Research Building, Suite 200
    Scottsdale, AZ 85259

    Mercantile Ascendency NewsWire
    Angela Junell